SHStephen T. Holgate

Stephen T. Holgate

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen T. Holgate has a total of 755 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • EAACI Guidelines on Environmental Science for Allergy and Asthma—Evidence‐Based Recommendations for Prevention and Public Health Action to Mitigate the Impact of Pollen Exposure on Respiratory Allergy

    by Lorenzo Cecchi, Isabella Annesi‐Maesano, Benedetta Biagioni, Kian Fan Chung, Bernard Clot, Gennaro D'AMato, Athanasios Damialis, Stefano Del Giacco, Javier Dominguez‐Ortega, Carmen Galán, et al.

    Developed using the GRADE methodology, these EAACI guidelines provide evidence‐based recommendations on the effectiveness of pollen reduction/avoidance strategies for allergic rhinitis (AR) and asthma, the utility of biomarkers for monitoring pollen‐induced asthma and the efficiency of mitigation measures and of public health strategies. Systematic and narrative reviews and health economic analysis support the recommendations. According to GRADE, the certainty of evidence was moderate to very low, therefore conditional recommendations are provided to guide healthcare professionals, patients, and policymakers in developing personalized, preventive, and scalable interventions. Reducing/avoiding exposure to pollen should be recommended to reduce the risk of severe asthma exacerbations. Lung function decrease and exhaled nitric oxide increase may be predictive for pollen‐induced asthma exacerbations. Real‐time pollen monitoring and pollen concentration‐based forecast may be recommended for managing pollen‐induced AR and/or asthma. Pollutant information should be included in pollen information systems. Combined forecast (weather, pollen, pollutants) and warning systems might reduce the impact of thunderstorm asthma (TA). Emergency department/asthma‐related services should be strengthened during pollen season and in TA. Personalized frameworks covering the types and allergenic potential of pollen, the coaggressors and the vulnerability of each patient are needed in daily practice. The fundamental role of prevention should be further prioritized.


  • Letter from the UK: Reflections on a turbulent 5 years

    by Stephen T. Holgate

  • Celebrating 75 years of BSACI

    by Pamela W. Ewan, Stephen R. Durham, Glenis K. Scadding, Stephen T. Holgate

  • Top Cited Papers

    Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

    by Marek Jutel, Ioana Agache, Magdalena Zemelka‐Wiacek, Mübeccel Akdis, Tomás Chivato, Stefano del Giacco, Pawel Gajdanowicz, Ibon Eguiluz Gracia, Ludger Klimek, Antti Lauerma, et al.

    The exponential growth of precision diagnostic tools, including omic technologies, molecular diagnostics, sophisticated genetic and epigenetic editing, imaging and nano‐technologies and patient access to extensive health care, has resulted in vast amounts of unbiased data enabling in‐depth disease characterization. New disease endotypes have been identified for various allergic diseases and triggered the gradual transition from a disease description focused on symptoms to identifying biomarkers and intricate pathogenetic and metabolic pathways. Consequently, the current disease taxonomy has to be revised for better categorization. This European Academy of Allergy and Clinical Immunology Position Paper responds to this challenge and provides a modern nomenclature for allergic diseases, which respects the earlier classifications back to the early 20th century. Hypersensitivity reactions originally described by Gell and Coombs have been extended into nine different types comprising antibody‐ (I‐III), cell‐mediated (IVa‐c), tissue‐driven mechanisms (V‐VI) and direct response to chemicals (VII). Types I‐III are linked to classical and newly described clinical conditions. Type IVa‐c are specified and detailed according to the current understanding of T1, T2 and T3 responses. Types V‐VI involve epithelial barrier defects and metabolic‐induced immune dysregulation, while direct cellular and inflammatory responses to chemicals are covered in type VII. It is notable that several combinations of mixed types may appear in the clinical setting. The clinical relevance of the current approach for allergy practice will be conferred in another article that will follow this year, aiming at showing the relevance in clinical practice where various endotypes can overlap and evolve over the lifetime.


  • Clinical trials of inhaled interferon beta-1a (SNG001) in COVID-19 patients in the home and hospital

    by Phillip D Monk, Jody Brookes, Victoria Tear, Toby Batten, Marcin Mankowski, Felicity Gabbay, Donna Davies, Chris Brightling, Monica Kraft, Ratko Djukanovic, et al.

    Background: Interferon beta (IFN-β), a key host antiviral mediator, can be suppressed by virus or host factors locally at the site of infection. Inhaled SNG001 (IFN-β-1a nebuliser solution) aims to restore lung IFN-β levels. In a Phase 2 trial hospitalised COVID-19 patients receiving SNG001 were more than twice as likely to recover, supporting progression to the Phase 3 SPRINTER trial in hospitalised patients and inclusion of SNG001 in the ACTIV-2 Phase 2/3 trial in non-hospitalised volunteers (Figure 1). The SPRINTER study did not meet its primary efficacy endpoints, hospital discharge and recovery, likely due to improved standard of care reducing the window to show a treatment effect. An encouraging signal for the key secondary endpoint, prevention of progression to severe disease or death (26% RRR;OR 0.71(0.44,1.15);p=0.161), was observed and supported by post hoc analyses of at risk groups. Results: In ACTIV-2 there were no statistically significant differences between SNG001 and placebo for the primary outcomes of safety (SNG001 was well-tolerated), symptom resolution, or virology. However, fewer participants required hospitalisation following SNG001 treatment (N=1/110, [1%]) compared to placebo (N=7/110, [6%]), 86% RRR (P=0.07). IDSMB recommended progression to Phase 3. Conclusions: SNG001 was well tolerated across trials and should continue to be investigated for COVID-19 in the home and hospital settings.

  • Open Access

    How can the public health community support litigation to protect public health in the context of climate change and other environmental threats to health?

    by Farhang Tahzib, Stephen Holgate, Brigit Toebes, David Patterson

    Outline: Climate change and environmental health are important cross-cutting issues to address within the public health sector. Encouraged by wins on asbestos and against big tobacco, the public health community and environmental advocates are turning to litigation to sue governments and private...

  • In memoriam: Lawrence M. Lichtenstein (1934–2022)

    by Gianni Marone, Massimo Triggiani, Vincenzo Casolaro, Cristiana Stellato, Amato de Paulis, Stephen T. Holgate, Cezmi A. Akdis, Stephen J. Galli

  • Open Access

    Contributors

    by Cezmi A. Akdis, Mübeccel Akdis, Fuad M. Baroody, Mark Boguniewicz, Simon G.A. Brown, A. Wesley Burks, Anca-Mirela Chiriac, Jonathan Corren, Adnan Custovic, Pascal Demoly, et al.

  • Open Access

    Accelerating the transition of clinical science to translational medicine

    by Stephen T. Holgate

    The SARS-CoV-2 pandemic has shown the importance of medical research in responding to the urgent prevention and health needs to combat the devastating disease, COVID-19, that this β-coronavirus unleashed. Equally, it has demonstrated the importance of interdisciplinary working to translate scientific discovery into public and patient benefit. As we come to adjust to live with this new virus, it is important to look back and see what lessons we have learnt in the way scientific medical discoveries can be more effectively and rapidly moved into public benefit. Clinical Science has had a long and distinguished history with this Journal bearing the same name and being an important contributor to the rapidly increasing use of human pathobiological data to gain mechanistic understanding of disease mechanisms leading to new diagnostic tests and treatments. The recognition that many complex diseases engage multiple causal pathways that may vary from patient to patient, and at different times across the lifecourse, has led to the emergence of stratified or precision medicine in which the right treatment is given to the right patient at the right time and, in doing so, minimise ‘non-responders’ and off-target side effects. Applications of omics technologies, the digitalisation of biology and the applications of machine learning and artificial intelligence (AI) are accelerating disease insights at pace with translation of discoveries into new diagnostic tests and treatments. The future of clinical science, as it morphs into translational medicine, is now creating unique possibilities where even the most intractable diseases are now open to being conquered.


  • Reducing the hidden burden of severe asthma: recognition and referrals from primary practice

    by Marc Humbert, Arnaud Bourdin, Nikolaos G. Papadopoulos, Stephen T. Holgate, Nicola A. Hanania, David M. G. Halpin, Kenneth R. Chapman, Marcela Gavornikova, David B. Price, Alan Kaplan, et al.

    Since their introduction many decades ago, systemic corticosteroids have become a mainstay treatment for asthma. Despite being a highly effective therapy, corticosteroids can cause significant adverse effects in patients. This results in a “double hit” for some patients as they suffer the burden of disease as well as the burden of treatment-induced morbidity. This article aims to raise awareness of the potential, harmful side effects of prolonged or repeated exposure to systemic corticosteroids in asthma. It also highlights the importance of referral of the appropriate patients with asthma from primary care for specialist assessment once other considerations such as adherence, inhaler technique and co-morbidity have been evaluated. We propose a simple decision step that may help busy primary care physicians and general practitioners to identify patients who could benefit from specialist assessment. Our decision step suggests that a patient with asthma should be reviewed at least once by an asthma specialist if he/she (i) has received ≥2 courses of oral corticosteroids in the previous year; asthma remains uncontrolled despite good adherence and inhaler technique; or (ii) has attended an emergency department or was hospitalised for asthma care. Such referral could facilitate wider access to diagnostic tools, in-depth assessment of confounding comorbidities, and non-corticosteroid-based therapies as needed, which may be unavailable in primary practice.